Immuneering Presented Preclinical Data At AACR Annual Meeting For Ongoing Phase 2a Clinical Trial Of IMM-1-104 In RAS-Mutated Advanced Or Metastatic Solid Tumors
Immuneering Presented Preclinical Data At AACR Annual Meeting For Ongoing Phase 2a Clinical Trial Of IMM-1-104 In RAS-Mutated Advanced Or Metastatic Solid Tumors
Globe Newswire
环球新闻专线
- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibition than either treatment alone -
-在 AACR 上公布的临床前数据表明，与单独使用任何一种疗法相比，将 IMM-1-104 与用于一线胰腺癌治疗的化疗结合可产生更深、更持久的肿瘤生长抑制作用-
- Patients are now on treatment in multiple arms of the ongoing Phase 2a trial, including multiple patients with pancreatic cancer who are being treated with IMM-1-104 in combination with chemotherapy in the first-line setting -
-患者目前正在进行的 2a 期试验的多个组中接受治疗，其中包括在一线环境中正在接受 IMM-1-104 联合化疗治疗的多名胰腺癌患者-
- Immuneering expects initial data from multiple IMM-1-104 Phase 2a arms in 2024 -
-Immuneering 预计 2024 年将有来自多个 IMM-1-104 第 2a 阶段组的初始数据-